l 753037 has been researched along with tezosentan in 1 studies
| Studies (l 753037) | Trials (l 753037) | Recent Studies (post-2010) (l 753037) | Studies (tezosentan) | Trials (tezosentan) | Recent Studies (post-2010) (tezosentan) |
|---|---|---|---|---|---|
| 18 | 1 | 1 | 157 | 29 | 33 |
| Protein | Taxonomy | l 753037 (IC50) | tezosentan (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.021 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0205 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berens, KL; Blok, N; Bourgoyne, AR; Brock, TA; Bui, H; Decker, ER; Dixon, RA; Holland, GW; Knowles, V; Wang, J; Wu, C; You, TJ | 1 |
1 trial(s) available for l 753037 and tezosentan
| Article | Year |
|---|---|
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Isoxazoles; Ligands; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Structure-Activity Relationship; Sulfones | 2004 |